Subjects n | 133 | 375 | 60 | |
RA dilatation | 75 (97) | 250 (97) | 60 (100) | 0.82 |
RV dilatation | 61 (79) | 206 (80) | 46 (77) | 0.90 |
TR jet velocity cm·s-1 | 407±71 | 405±73 | 435±61 | 0.74 |
Positive bubble study | 8 (10) | 27 (11) | 4 (7) | 0.97 |
RVSP mmHg | 73±23 | 74±24 | 77±27 | 0.68 |
sPAP mmHg | 74±19 | 75±21 | 81±23 | 0.41 |
dPAP mmHg | 30±9 | 32±11 | 35±12 | 0.08 |
mPAP mmHg | 45±11 | 47±14 | 51±16 | 0.08 |
PCWP mmHg | 9±3 | 10±6 | 10±3 | 0.16 |
Pulmonary vascular resistance Wood units | 9±5 | 10±6 | 11±7 | 0.16 |
Cardiac index (Fick) L·min-1·m-2 | 2.6±0.9 | 2.4±2 | 2.5±1.8 | 0.04 |
Cardiac output (Fick) L·min-1 | 4.9±2 | 4.5±2 | 4.5±2 | 0.04 |
Pulmonary arterial oxygen saturation % | 63±12 | 64±13 | 62±11 | 0.41 |
PAH medications | | | | |
Epoprostenol | 33 (25) | 127 (34) | 21 (35) | 0.05 |
Sildenafil | 66 (50) | 144 (38) | 28 (46) | 0.02 |
Bosentan | 32 (24) | 112 (30) | 20 (33) | 0.20 |
Treprostinil | 11 (8) | 41 (11) | 8 (13) | 0.37 |
Ambrisentan | 15 (11) | 18 (5) | 9 (15) | 0.10 |
Tadalafil | 12 (9) | 19 (5) | 6 (10) | 0.10 |
Iloprost | 4 (3) | 11 (3) | 3 (5) | 0.96 |
Oxygen therapy | 29 (22) | 84 (23) | 17 (28) | 0.86 |